耳鼻咽喉科・頭頸部外科91巻1号

2019年01月発行

特集 役に立つ！ アレルギー診療の最新情報

舌下免疫療法の現状と今後の展望

著者： 岡野光博¹

所属機関： ¹国際医療福祉大学医学部耳鼻咽喉科学

ページ範囲：P.26 - P.32

文献概要

POINT

●現状ではダニによるアレルギー性鼻炎とスギ花粉症に適応がある。

●長期的な寛解効果を期待するのであれば3年間以上の治療が望ましい。

●5歳以上の小児にも治療が可能となった。

●今後の課題として，2種舌下免疫療法（dual SLIT）やヒノキ花粉による舌下免疫療法の開発などがある。

参考文献

1）岡野光博：アレルゲン免疫療法の適応と禁忌．アレルギー性鼻炎に対する免疫療法の実際と対応，一般社団法人免疫療法臨床研究会（編）．2017，pp22-30

2）Sakashita M, et al：Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a. Cytokine 75：181-185, 2015

3）Okamoto Y, et al：House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy 72：435-443, 2017

4）Scadding GW, et al：Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis：The GRASS randomized clinical trial. JAMA 317：615-625, 2017

5）O'Hehir RE, et al：House dust mite sublingual immunotherapy：the role of transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 180：936-947, 2009

6）de Bot CM, et al：Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 23：150-158, 2012

7）Okubo K, et al：A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int 57：265-275, 2008

8）Okamoto Y, et al：Efficacy and safety of sublingual immunotherapy for two seasons：in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 166：177-188, 2015

9）Radulovic S, et al：Systematic reviews of sublingual immunotherapy（SLIT）. Allergy 66：740-752, 2011

10）Okamoto Y, et al：Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis：A randomized trial in a pediatric population. Pediatr Allergy Immunol, 2018［Epub ahead of print］

11）Valovirta E, et al：Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention（GAP）trial in children with grass pollen allergy. J Allergy Clin Immunol 141：529-538, 2018

12）Di Lorenzo G, et al：Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 123：1103-1110, 2009

13）Maloney J, et al：Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. J Allergy Clin Immunol Pract 4：301-309, 2016

14）品川 潤・他：皮下免疫療法から二種舌下免疫療法（Dual SLIT）に切り替えたアレルギー性鼻炎症例．日鼻誌56：479，2017

15）Haruna T, et al：Role of whole saliva in tha efficacy of sublingual immunotherapy in seasonal allergic rhinitis. Allergol Int, 2018［Epub ahead of print］

16）Okano M, et al：Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis. J Allergy Clin Immunol 127：277-279, 2011

17）湯田厚司・他：スギ花粉舌下免疫療法のヒノキ花粉飛散期の臨床効果．日耳鼻120：833-840，2017

18）Osada T, et al：Identification and gene cloning of a new major allergen Cha o 3 from Chamaecyparis obtuse（Japanese cypress）pollen. J Allergy Clin Immunol 138：911-913, 2016

19）Osada T, et al：Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica（Japanese cedar）pollen：Limitation of the present Japanese cedar-specific ASIT. Allergol Int 67：467-474, 2018